Prasugrel or Ticagrelor in ST-Segment–Elevation Myocardial Infarction Patients With Diabetes Mellitus
| Autor: | Rocco Stio, Simone Calcagno, Riccardo Colantonio, Massimo Mancone, Erika Cavallo, Gennaro Sardella, Angelo Di Roma |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Prasugrel medicine.medical_treatment 030204 cardiovascular system & hematology ticagrelor 03 medical and health sciences platelet antagonists 0302 clinical medicine P2Y12 Physiology (medical) Internal medicine medicine cardiovascular diseases 030212 general & internal medicine Myocardial infarction Morphine cloride myocardial infarction platelet function test prasugrel hydrochloride cardiology and cardiovascular medicine physiology (medical) Stroke Aspirin Prasugrel Hydrochloride business.industry Percutaneous coronary intervention medicine.disease Cardiology Cardiology and Cardiovascular Medicine business Ticagrelor medicine.drug |
| Zdroj: | Circulation. 136:602-604 |
| ISSN: | 1524-4539 0009-7322 |
| Popis: | Prasugrel or ticagrelor is recommended in patients with ST-segment–elevation myocardial infarction (STEMI). Patients with diabetes mellitus are characterized by enhanced platelet reactivity (PR) and a reduced response to oral antiplatelet agents.1 The RESET 2D trial (Prasugrel vs Ticagrelor in ST-Elevation Myocardial Infarction Patients With Diabetes Mellitus) was a prospective, randomized, pharmacodynamic study evaluating platelet inhibition by loading dose (LD) of ticagrelor or prasugrel in P2Y12-naive patients with diabetes mellitus presenting with STEMI. The local ethics committee approved the study (ClinicalTrials.gov NCT01531114). All consecutive patients with STEMI with diabetes mellitus undergoing primary percutaneous coronary intervention who were P2Y12 naive were considered for PR assessment. Major exclusion criteria were bleeding diathesis, periprocedural glycoprotein IIb/IIIa receptor inhibitor use, morphine administration, previous ischemic/hemorrhagic stroke, and any contraindication to antiplatelet therapy. Eligible patients were randomized 1:1 to receive ticagrelor 180-mg LD or prasugrel 60-mg LD at the time of percutaneous coronary intervention. All patients received oral aspirin 325 mg and intravenous unfractionated heparin (70 U/kg). Platelet function testing was performed with VerifyNow (Accumetrics, San Diego, CA) at baseline and … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|